TIAA CREF Investment Management LLC raised its stake in shares of Impax Laboratories, Inc. (NASDAQ:IPXL) by 1.0% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 238,473 shares of the specialty pharmaceutical company’s stock after purchasing an additional 2,463 shares during the period. TIAA CREF Investment Management LLC owned 0.33% of Impax Laboratories worth $3,839,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in Impax Laboratories by 4.6% during the first quarter. Vanguard Group Inc. now owns 6,251,395 shares of the specialty pharmaceutical company’s stock valued at $79,080,000 after purchasing an additional 276,765 shares during the period. Dimensional Fund Advisors LP grew its holdings in Impax Laboratories by 47.2% during the first quarter. Dimensional Fund Advisors LP now owns 2,637,077 shares of the specialty pharmaceutical company’s stock valued at $33,359,000 after purchasing an additional 845,375 shares during the period. Frontier Capital Management Co. LLC grew its holdings in Impax Laboratories by 43.2% during the second quarter. Frontier Capital Management Co. LLC now owns 1,585,828 shares of the specialty pharmaceutical company’s stock valued at $25,532,000 after purchasing an additional 478,168 shares during the period. Point72 Asset Management L.P. grew its holdings in Impax Laboratories by 88.4% during the first quarter. Point72 Asset Management L.P. now owns 1,095,600 shares of the specialty pharmaceutical company’s stock valued at $13,859,000 after purchasing an additional 514,200 shares during the period. Finally, Principal Financial Group Inc. grew its holdings in Impax Laboratories by 4.1% during the first quarter. Principal Financial Group Inc. now owns 576,949 shares of the specialty pharmaceutical company’s stock valued at $7,298,000 after purchasing an additional 22,713 shares during the period. 86.26% of the stock is owned by institutional investors and hedge funds.

Several analysts have issued reports on the company. Zacks Investment Research lowered Impax Laboratories from a “hold” rating to a “sell” rating in a report on Friday. Royal Bank Of Canada set a $17.00 price target on Impax Laboratories and gave the company a “hold” rating in a report on Tuesday, October 17th. Canaccord Genuity set a $19.00 price target on Impax Laboratories and gave the company a “hold” rating in a report on Tuesday, October 17th. Cantor Fitzgerald set a $25.00 price target on Impax Laboratories and gave the company a “buy” rating in a report on Tuesday, October 17th. Finally, Goldman Sachs Group, Inc. (The) assumed coverage on Impax Laboratories in a report on Thursday, September 28th. They set a “neutral” rating and a $20.00 price target for the company. Four investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and five have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $18.92.

TRADEMARK VIOLATION NOTICE: “TIAA CREF Investment Management LLC Buys 2,463 Shares of Impax Laboratories, Inc. (IPXL)” was originally reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/tiaa-cref-investment-management-llc-buys-2463-shares-of-impax-laboratories-inc-ipxl/1647046.html.

Shares of Impax Laboratories, Inc. (NASDAQ:IPXL) opened at 21.25 on Friday. The stock’s market capitalization is $1.53 billion. Impax Laboratories, Inc. has a 52-week low of $7.75 and a 52-week high of $25.70. The company has a 50 day moving average price of $21.43 and a 200-day moving average price of $17.41.

Impax Laboratories (NASDAQ:IPXL) last posted its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.18 EPS for the quarter, beating the Zacks’ consensus estimate of $0.14 by $0.04. Impax Laboratories had a positive return on equity of 9.05% and a negative net margin of 71.08%. The firm had revenue of $202.08 million for the quarter, compared to analysts’ expectations of $195.62 million. During the same period last year, the firm earned $0.21 EPS. The company’s quarterly revenue was up 17.1% on a year-over-year basis. On average, analysts predict that Impax Laboratories, Inc. will post $0.70 earnings per share for the current fiscal year.

About Impax Laboratories

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Want to see what other hedge funds are holding IPXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Impax Laboratories, Inc. (NASDAQ:IPXL).

Institutional Ownership by Quarter for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.